Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Regulation of advanced therapy medicinal products in Europe and the role of academia

In English

Författare

  • Kim F. Pearce
  • Martin Hildebrandt
  • Hildegard Greinix
  • Stefan Scheding
  • Ulrike Koehl
  • Nina Worel
  • Jane Apperley
  • Matthius Edinger
  • Andrea Hauser
  • Eva Mischak-Weissinger
  • Anne M. Dickinson
  • Mark W. Lowdell
Visa allt

Summary, in English

Background aims. Advanced therapy medicinal products (ATMP) are gene therapy, somatic cell therapy or tissue-engineered products regulated under (EC) No. 1394/2007 to ensure their free movement within the European Union while guaranteeing the highest level of health protection for patients. Academic good manufacturing practice (GMP) centers are major contributors in the development of ATMPs and this study assessed the impact of regulations on them. Methods. European academic and non-industrial facilities (n = 747) were contacted, and a representative sample of 50 replied to a detailed questionnaire. Experienced centres were further selected in every Member State (MS) for semi-structured interviews. Indicators of ATMP production and development success were statistically assessed, and opinions about directive implementation were documented. Results. Facilities experienced in manufacturing cell therapy transplant products are the most successful in developing ATMPs. New centres lacking this background struggle to enter the field, and there remains a shortage of facilities in academia participating in translational research. This is compounded by heterogeneous implementation of the regulations across MS. Conclusions. GMP facilities successfully developing ATMPs are present in all MS. However, the implementation of regulations is heterogeneous between MS, with substantial differences in the definition of ATMPs and in the approved manufacturing environment. The cost of GMP compliance is underestimated by research funding bodies. This is detrimental to development of new ATMPs and commercialization of any that are successful in early clinical trials. Academic GMP practitioners should strengthen their political visibility and contribute to the development of functional and effective European Union legislation in this field.

Publiceringsår

2014

Språk

Engelska

Sidor

289-297

Publikation/Tidskrift/Serie

Cytotherapy

Volym

16

Issue

3

Dokumenttyp

Artikel i tidskrift

Förlag

Taylor & Francis

Ämne

  • Cell and Molecular Biology

Nyckelord

  • advanced therapy medicinal products
  • European Union
  • good manufacturing
  • practice
  • manufacturing
  • regulation

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1477-2566